www.fdanews.com/articles/152604-vanda-announces-positive-results-in-the-second-phase-iii-study-of-tasimelteon

Vanda Announces Positive Results in the Second Phase III Study of Tasimelteon

January 23, 2013

Vanda Pharmaceuticals announced positive results for the second Phase III study of tasimelteon for the treatment of Non-24-Hour Disorder.
Benzinga